open access

Vol 14, No 1 (2017)
Review paper
Published online: 2017-03-01
Get Citation

All we need to know about neuroleptic malignant syndrome

Anna Mosiołek, Dariusz Galanty
Psychiatria 2017;14(1):28-34.

open access

Vol 14, No 1 (2017)
Prace poglądowe - nadesłane
Published online: 2017-03-01

Abstract

One of the rarest but unfortunately undoubtedly the most dangerous complications in pharmacotherapy treatment of mental disorders is neuroleptic malignant syndrome (NMS). Most often it arises as a result of the use of antipsychotics, but there are also cases, described in the literature, of NMS which starts as a result of usage antidepressants such as mianserin, amoxapine, or fluoxetine. Neuroleptic malignant syndrome has also been found in patients diagnosed with Parkinson’s disease and parkinsonism, after abrupt discontinuation of usage of L-dopa and drugs that are dopamine receptor agonists (cabergoline, bromocriptine, pergolide, ropinirole, pramipexole, and amantadine). Symptoms that may suggest the occurrence of neuroleptic malignant syndrome are low muscle tone, fluctuations in blood pressure, tachycardia, arrhythmias, increased or very high body temperature, sweating, confusion, dysarthria, or urinary retention, psychomotor agitation, tremors, drooling, or shortness of breath.

Abstract

One of the rarest but unfortunately undoubtedly the most dangerous complications in pharmacotherapy treatment of mental disorders is neuroleptic malignant syndrome (NMS). Most often it arises as a result of the use of antipsychotics, but there are also cases, described in the literature, of NMS which starts as a result of usage antidepressants such as mianserin, amoxapine, or fluoxetine. Neuroleptic malignant syndrome has also been found in patients diagnosed with Parkinson’s disease and parkinsonism, after abrupt discontinuation of usage of L-dopa and drugs that are dopamine receptor agonists (cabergoline, bromocriptine, pergolide, ropinirole, pramipexole, and amantadine). Symptoms that may suggest the occurrence of neuroleptic malignant syndrome are low muscle tone, fluctuations in blood pressure, tachycardia, arrhythmias, increased or very high body temperature, sweating, confusion, dysarthria, or urinary retention, psychomotor agitation, tremors, drooling, or shortness of breath.

Get Citation

Keywords

neuroleptic malignant syndrome, neuroleptics, treatment

About this article
Title

All we need to know about neuroleptic malignant syndrome

Journal

Psychiatria (Psychiatry)

Issue

Vol 14, No 1 (2017)

Article type

Review paper

Pages

28-34

Published online

2017-03-01

Bibliographic record

Psychiatria 2017;14(1):28-34.

Keywords

neuroleptic malignant syndrome
neuroleptics
treatment

Authors

Anna Mosiołek
Dariusz Galanty

References (13)
  1. Meder J, Jarema M, Adamska-Węgrzyn E, et al. Stany nagłe w psychiatrii. Psychiatria Polska 2007. 2007; XLI(6): 871–938.
  2. Petit JR. Psychiatria ratunkowa. Urban & Partner, Wrocław 2007: 161–282.
  3. Rabe-Jabłońska J, Pawełczyk T, Strzelecki D. Przewodnik psychofarmakoterapii. Działania niepożądane i powikłania. Via Medica, Gdańsk 2010: 32–146.
  4. Frontera JA. Stany zagrożenia życia w neurologii klinicznej. Wydawnictwo Lekarskie PZWL, Warszawa 2011: 171–361.
  5. Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011; 72(9): 1222–1228.
  6. Urząd Rejestracji Produktów leczniczych Wyrobów Medycznych i Produktów Biobójczych, Charakterystyki produktów leczniczych: Deprexolet, Lerivon, Miansec, Miansegen, Andepin, Bioxetin, Deprexetin, Fluoksetyna ANPHARM, Fluoxetin Polpharma, Seronil, Fluxemed. 2013, leki.urpl.gov.pl/index.php.
  7. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989; 50(1): 18–25.
  8. Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007; 164(6): 870–876.
  9. Bogucki A,Gajos A,Cybertowicz M. Stany nagłe w pozapiramidowych zaburzeniach ruchowych — diagnostyka i postępowanie. Polski Przegląd Neurologiczny 2006; 2(4): 183–189.
  10. Hauser SL, Josephson SA. Harrison. Neurologia w medycynie klinicznej. tom I. Wydawnictwo Czelej, Lublin 2012: 403, 413.
  11. Velamoor VR, Norman RM, Caroff SN, et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 1994; 182(3): 168–173.
  12. Chwalibogowska-Podlewska A, Podlewski JK. Leki współczesnej terapii wydanie XIX. Medical Tribune Polska, Warszawa 2009: 220–221.
  13. Rana A., Morren J.A. Neuroleptic malignant syndrome (NMS). Neurological Emergencies in Clinical Practice.  Springer Verlag, London 2013: 109–111.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl